We have recently commenced a new study funded and sponsored by F. Hoffman La Roche Ltd and led at Nottingham by Professor Ian Hall of the NIHR Nottingham BRC and the University of Nottingham.
A PHASE IB, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SELNOFLAST IN PARTICIPANTS WITH MODERATE TO SEVERE ASTHMA
Why are we doing the study?
The purpose of this study is to find out whether selnoflast has any effects (good or bad), what happens to selnoflast once it is in your body, and what selnoflast does to your body and your disease compared with placebo. A placebo is a pill or medicine that looks like a drug but has no active medicinal ingredients that can have an effect on your health. Placebos are commonly used in studies to see if the effects experienced by participants while taking a study treatment are really the result of the treatment instead of other causes.
Approximately 27 people with asthma will take part in this study in the UK and 60 to 90 people globally.
Selnoflast is an experimental drug, which means that Health Authorities (like the U.S. Food and Drug Administration, Health Canada, Medicines and Healthcare products Regulatory Agency, and European Medicines Agency) have not approved selnoflast for the treatment of asthma.
Selnoflast has been tested in healthy people and in people with ulcerative colitis. It is also being tested in other studies in people with Parkinson’s disease and people with coronary artery disease.